Amgen 2012 Annual Report Download - page 66

Download and view the complete annual report

Please find page 66 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

59
Item 6. SELECTED FINANCIAL DATA
Years ended December 31,
Consolidated Statement of Income Data: 2012 2011 2010 2009 2008
(In millions, except per share data)
Revenues:
Product sales $ 16,639 $ 15,295 $ 14,660 $ 14,351 $ 14,687
Other revenues 626 287 393 291 316
Total revenues 17,265 15,582 15,053 14,642 15,003
Operating expenses:
Cost of sales (excludes amortization of
certain acquired intangible assets
presented separately) 2,918 2,427 2,220 2,091 2,296
Research and development 3,380 3,167 2,894 2,864 3,030
Selling, general and administrative 4,801 4,486 3,983 3,820 3,789
Amortization of certain acquired
intangible assets 294 294 294 294 294
Other(1) 295 896 117 67 380
Net income 4,345 3,683 4,627 4,605 4,052
Diluted earnings per share 5.52 4.04 4.79 4.51 3.77
Dividends paid per share 1.44 0.56 — — —
As of December 31,
Consolidated Balance Sheet Data: 2012 2011 2010 2009 2008
(In millions)
Total assets $ 54,298 $ 48,871 $ 43,486 $ 39,629 $ 36,427
Total debt(2) 26,529 21,428 13,362 10,601 9,352
Total stockholders’ equity(3) 19,060 19,029 23,944 22,667 20,885
In addition to the following notes, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results
of Operations and the Consolidated Financial Statements and accompanying notes and previously filed Annual Reports on Form
10-K for further information regarding our consolidated results of operations and financial position for periods reported therein
and for known factors that will impact comparability of future results. Also, see Item 5. Market for Registrant’s Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities for information regarding cash dividends declared per share
of common stock.
(1) In 2011, we recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in
principle to settle allegations related to our sales and marketing practices. In 2008, we recorded loss accruals for settlements
of certain commercial legal proceedings aggregating $288 million, related principally to the settlement of the Ortho Biotech
Products L.P. antitrust suit.
(2) See Note 14, Financing arrangements, to the Consolidated Financial Statements for discussion of our financing arrangements.
In addition, in 2009 and 2008, we issued $2.0 billion and $1.0 billion, respectively, aggregate principal amount of notes. In
2009 and 2008 we repaid $1.0 billion of fixed interest rate notes and $2.0 billion of floating-rate notes, respectively.
(3) Throughout the five years ended December 31, 2012, we had a share repurchase program authorized by the Board of Directors
through which we repurchased $4.7 billion, $8.3 billion, $3.8 billion, $3.2 billion and $2.3 billion, respectively, of Amgen
common stock.